According to the popularly cited study from Tufts Center for the Study of Drug Development, it costs $2.6 billion to receive a drug approval.1 Despite the increased investments and revolutionary therapies brought to market, return on investment from drug launches is near historical lows.2 Luckily, issues such as challenging physicochemical properties and unfavorable absorption characteristics can be addressed early in the development process. Screening formulation options in the pre-clinical setting has the potential to reduce both costs and risk of attrition.
Bringing Poorly Soluble Molecules to Market with Bioavailability Enhancement Technologies